Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Pfizer acquired both Xtandi and Talzenna, a PARP inhibitor, in its $14 billion buyout of Medivation in 2016.
And in its Phase III TALAPRO-2 study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
